Department of Pediatric Gastroenterology and Nutrition, The Medical University of Warsaw, Warsaw, Poland.
Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Warsaw, Poland.
Hum Vaccin Immunother. 2021 Aug 3;17(8):2586-2592. doi: 10.1080/21645515.2021.1884475. Epub 2021 Apr 1.
The cholera vaccine can protect patients with inflammatory bowel disease (IBD) against both cholera and travelers' diarrhea. However, both immunosuppressive treatment and IBD can affect its vaccine immunogenicity. The aim of this study was to assess the immunogenicity and safety of the cholera vaccine in children with IBD. Children older than 6 years with diagnosed IBD were enrolled in this multicenter study. All patients were administered two doses of the oral cholera vaccine (Dukoral®). Anti-cholera toxin B subunit IgA and IgG seroconversion rates were evaluated in a group with immunosuppressive (IS) treatment and a group without IS treatment (NIS). Immunogenicity was assessed in 70 children, 79% of whom received IS treatment. Post-vaccination seroconversion was displayed by 33% of children, for IgA, and 70% of children, for IgG. No statistically significant differences were found in the immune responses between the IS and NIS groups: 35% vs. 27% ( = .90), for IgA, and 68% vs. 80.0% ( = .16), for IgG, respectively. One case of IBD exacerbation after vaccination was reported. The oral cholera vaccine is safe. The immunogenicity of the oral cholera vaccine in children with IBD was lower than previously observed in healthy ones. The treatment type does not seem to affect the vaccine immunogenicity.
霍乱疫苗可预防炎症性肠病（IBD）患者感染霍乱和旅行者腹泻。然而，免疫抑制治疗和 IBD 均可影响疫苗的免疫原性。本研究旨在评估霍乱疫苗在 IBD 儿童中的免疫原性和安全性。本多中心研究纳入了诊断为 IBD 的 6 岁以上儿童。所有患者均接受了两剂口服霍乱疫苗（Dukoral®）。在接受免疫抑制（IS）治疗的组和未接受 IS 治疗的组（NIS）中，评估了抗霍乱毒素 B 亚单位 IgA 和 IgG 血清转化率。在 70 名接受免疫接种的儿童中评估了免疫原性，其中 79%接受 IS 治疗。接种疫苗后，IgA 血清转化率为 33%，IgG 血清转化率为 70%。IS 组和 NIS 组之间的免疫反应无统计学差异：IgA 分别为 35%和 27%（ = 0.90），IgG 分别为 68%和 80.0%（ = 0.16）。接种疫苗后报告了 1 例 IBD 加重病例。口服霍乱疫苗是安全的。与健康人群相比，IBD 儿童口服霍乱疫苗的免疫原性较低。治疗类型似乎不影响疫苗的免疫原性。
